Richard Malley

Malley Rick 250

Under Dr. Porter Anderson’s mentorship, Dr. Malley focused his early career on the development of novel vaccines against pneumococcus, leading to numerous scientific publications describing pneumococcal pathogenesis and prevention, such as acquired and innate immunity, correlates of protection, and mechanisms of protection from nasopharyngeal colonization. In collaboration with PATH and the Bill and Melinda Gates Foundation, Dr. Malley led an international effort for the development of a whole-cell killed pneumococcal vaccine for developing countries. A Phase I trial of the whole cell vaccine was successfully completed in 2012 in the US, and a Phase II trial in toddlers is ongoing in Kenya. Work in his laboratory now focuses on vaccine development for this pathogen, Staphylococcus aureus, Salmonella typhi and paratyphi, and Mycobacterium tuberculosis. In 2014, Dr. Malley and collaborators started Affinivax, a company dedicated to the development of novel vaccines.

TPL_asm2013_ADDITIONAL_INFORMATION

TPL_asm2013_SEARCH

6571:richard-malley